Menu
Not yet recruiting NCT05718986

Familial B-cell Lymphoproliferative Disorders

— Observational Lymphoproliferative Disorders Premalignant Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukemia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No intervention.
Who it may be relevant to
Registry conditions: Lymphoproliferative Disorders, Premalignant, Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Epidemiology of Familial B-cell Lymphoproliferative Disorders

Overview

This study investigates families with at least two cases of B-cell lymphoproliferative disorders (LPD), and evaluates the prevalence of LPD in families, the relationship between medical history, genetic factors, and the risk of familial LPD, and various clinical outcomes for these families in a multiethnic population of Jews and Arabs in Israel.

Interventions

  • Other No intervention
    No intervention

Primary outcome measures

  • Prevalence of familial LPD in Israel [Time frame: 5 years]
  • Association between medical history and genetic variants and the risk of familial LPD [Time frame: 5 years]
  • Risk of clinical outcomes among familial LPD and family members [Time frame: 15 years]

Eligibility criteria

Inclusion criteria

  • Patient inclusion criteria:

Patients must have LPD and must have a family history of LPD. LPD patients who signed an informed consent to participate in the study.

Criteria for the inclusion of relatives of patients:

Relatives must be related by blood to LPD patients or unrelated (for control group).

Relatives who signed an informed consent to participate in the study.

Exclusion criteria

  • Pregnant women, special populations and those lacking judgment will not be included

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Family-based

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05718986 · FamilialLPD

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗